TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Impact on work activity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: percentage TIR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived hypoglycemia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Access to surgical care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in markers of Alzheimer's disease pathophysiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in complications
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in pain and negative emotion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: embarrassment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR50/70 achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area and Severity Index 75/90/100 achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absolute Error (MAE) between PCT and SCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute point dose deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gamma passing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMD-17 remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in PPD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LBP related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Flare size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Help-seeking intention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Circulating PLIN3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutritional status (BMI, ALB, PA, Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS-arm
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS-neck
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical Activity Enjoyment Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ISI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 14-day overall mortality
Endpoint domain: Mortality/survival
Primary endpoint: Discordance for administration of pain management 'other' than analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discordance for administration of oral analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discordance for administration of 'any' analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staff contamination during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Staff comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impressions of patient safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Kansas City Cardiomyopathy Questionnaire Overall Summary score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PL rate before gw22
Endpoint domain: Mortality/survival
Primary endpoint: Pre‐Prenatal Screening Period fetal losses
Endpoint domain: Mortality/survival
Primary endpoint: time to ambulation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Calculated blood loss at POD3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: biochemical RFS
Endpoint domain: Mortality/survival
Primary endpoint: local RFS
Endpoint domain: Mortality/survival
Primary endpoint: distant RFS
Endpoint domain: Mortality/survival
Primary endpoint: Breathlessness response during CPET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numbness degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔE at 180-day follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental sensitivity within 24 h
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective well-being regarding family and social life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: glomerular filtration rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: motor evoked potential (MEP) facilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GABA‐A‐ergic neurotransmission modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: D-Dimer values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD4+ and CD8+ T cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scheduling an adolescent well-care visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association of apolipoproteins and CRP with Alzheimer's Disease (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical failure outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liking of fruits and vegetables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion independence (TI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for well-differentiated TSCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for poorly differentiated TSCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for well-differentiated TSCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CAQ scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nonfatal cardiovascular events and cardiovascular-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: HAI IR (Hospital-Acquired Infection Incidence Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bias in MSPE language
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual Analog Scale (VAS) for postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery (QoR15) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: tinnitus-related distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence rate of SSEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first SSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom severity on the Patient Health Questionnaire‐9 (PHQ‐9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥50% reduction in symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of ≥5 PHQ‐9 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in daily forced expectoration and dry coughs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in all domains of the CASA-Q
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Better scores in the anxiety/depression domain of the EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of splint-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective improvement of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CR status prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean heart rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in CO2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial satiety volume improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum tolerable volume improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 1-year mortality estimates
Endpoint domain: Mortality/survival
Primary endpoint: Skeletal Muscle Index (SMI) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry socket incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Bone regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease in post-operative infections
Endpoint domain: Adverse events/effects
Primary endpoint: PASI-90 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: investigator global assessment 0/1 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tea yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tea quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average net income
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MCL grade achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for optimization maneuvers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity for nodule identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rate at 3 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention rate at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ability to function in daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SPD remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: muscle atrophy of RFCSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Leptin change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean size of the largest diameter of lesions’ induration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced joint damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Women’s satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: median time to treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in 24-hour UOx level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in nephrocalcinosis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney stone event rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg stiffness (Kleg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spo2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance scores of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to medical treatment at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Masseter muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: swing-phase duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Achievement of ACR50 and PASI100 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease state of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative fibrinogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Significant ABI (post-ablation relative increase of S100B level >30%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: knowledge and self-efficacy scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: frequency of breakfast intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: crisps consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of leukemia
Endpoint domain: Mortality/survival
Primary endpoint: normalized creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: yield of adequate histologic samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic accuracy of histologic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic accuracy of combined cytologic and histologic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients positive for anti-HLA class I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time for normalized Tinnitus Questionnaire scores to decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-m walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of progressing to severe depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean intention scores for the innovation and control groups
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: modified Ashworth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: GMFM‐88 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: UEFT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Satisfaction with assessment package
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Whitening efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall diet quality of the shopping basket
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feed Conversion Ratio (FCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GH <1.0 µg/L and normal IGF‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in key symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: TBUT increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal staining absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in melanin index (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in erythema index (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in absolute alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Decrease in P. gingivalis IgG antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Migraine-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patients' global impression of change with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: legs bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: femoral neck bone mineral content/bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: third lumbar vertebra bone mineral content/bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: composite ACP documentation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-excision rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in SDLRS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in PSI
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Iodine uptake (IU) as a predictor of early therapy response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in systolic blood pressure (SBP) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in diastolic blood pressure (DBP) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving good blood pressure control (<140/90 mmHg) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6-month target lesion failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: paCO2 decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: oxygenation increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chondrogenic capability of hFCSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOX9 expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement with FEES (validity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counseling for endorsed risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk behavior scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mindfulness and well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cautiousness about undertaking behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Acceptance of behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: MSFC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Illness-related parenting stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Individual LESS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in microbial aerosols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum RANKL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satisfaction rating for treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of pleasant activities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Enjoyment of pleasant activities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline on the Vineland‐II 2DC score at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI and DHKSS scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dissolved sludge in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes